Thormohlensgt 51, 5006
85 articles with BerGenBio AS
BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019
BerGenBio ASA notes the publication of abstracts relating to new interim clinical and biomarker data that the company and its collaborators will present from its extensive Phase II clinical development programme with bemcentinib at the 2019 annual meeting of the American Society of Clinical Oncology at McCormick Place in Chicago, Illinois.
BerGenBio Completes Recruitment Into Second Stage of Phase II Trial With Selective AXL inhibitor bemcentinib in Combination with KEYTRUDA® in Patients With Advanced NSCLC
Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy (Cohort A, NCT03184571)
BerGenBio ASA selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2019.
BerGenBio ASA, will announce its results for the first quarter on Wednesday, 8 May 2019.
BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019
Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA
BerGenBio ASA announces that Richard Godfrey, BerGenBio's Chief Executive Officer, will present an overview of the Company at the H.C. Wainwright Global Life Sciences Conference, April 9, 2019.
BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy
First patient dosed in new cohort of Phase II trial evaluating selective AXL inhibitor bemcentinib in combination with KEYTRUDA in patients with advanced NSCLC whose disease is progressing on anti-PD(L)1 therapy
BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance
Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing tumour-mediated immunosuppression and therapy resistance presented at AACR
BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients
Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for intensive therapy
The report is attached and available for download at www.bergenbio.com in the section: Investors/Financial Reports.
Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and NSCLC confirmed as target indications for forward development towards registration, starting in 2019 Increasing confidence in bemcentinib safety profile with more than 250 patients dosed
BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio's second novel clinical candidate targeting AXL Phase I study will investigate safety and pharmacokinetics in healthy volunteers [09-January-2019] BERGEN, Norway, Jan. 9 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage bioph
BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in High-risk MDS
Phase II monotherapy study of bemcentinib in high-risk MDS & AML
BerGenBio Presents Key Results From PhII Programme With Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference
Bemcentinib proof of concept clinical data as monotherapy and in combination confirms focus on lung cancer & leukaemia
BerGenBio Reports 43% Response Rate With Bemcentinib Monotherapy in AXL Positive R/R AML/MDS Patients at ASH
43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14)
BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.
Phase II data in NSCLC with bemcentinib/KEYTRUDA combination: First stage of trial in previously treated patients reported 40% ORR and ca. 6 months median PFS in AXL positive patients, stage 2 actively enrolling patients
BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial
Late breaking abstract at SITC: Analysis of first stage of phase II trial with selective AXL inhibitor bemcentinib + KEYTRUDA in previously treated advanced NSCLC patients
BerGenBio ASA will announce its results for the third quarter 2018 on Tuesday, 13 November 2018.
BerGenBio to Present Late-breaking Abstract on Phase II Trial of Bemcentinib in Combination With KEYTRUDA® in Advanced NSCLC at SITC
Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC